FDG PET/CT用于恶性间皮瘤的分期与再分期
本文综述[18F]FDG PET/CT在恶性间皮瘤分期与再分期中的作用。恶性间皮瘤侵袭性强、预后差,胸膜受累最常见,腹膜受累少见;WHO将其分为上皮样、双相型和肉瘤样组织学亚型,其中肉瘤样或双相型预后最差。由于呈独特的环状生长模式,间皮瘤的影像评估对影像医生颇具挑战;传统影像以增强CT为主,功能与代谢影像被视为补充手段。
要点
- 恶性间皮瘤侵袭性强、预后差,胸膜受累最常见,腹膜受累少见。
- WHO将间皮瘤分为上皮样、双相型和肉瘤样亚型,肉瘤样或双相型预后最差。
- 间皮瘤呈环状生长模式,影像评估困难;传统影像以增强CT为主,功能与代谢影像为补充。
核心结论
- 本文聚焦[18F]FDG PET/CT在恶性间皮瘤分期与再分期中的作用,总结文献现有数据,并对替代影像与未来前景提供提示。
- 鉴于胸膜病变占主导,大部分信息针对恶性胸膜间皮瘤,同时概述腹膜间皮瘤患者的主要特征与影像表现。
研究设计与样本
- 本文为综述,聚焦[18F]FDG PET/CT在恶性间皮瘤分期与再分期中的作用,总结文献现有数据。
主要发现
- 恶性间皮瘤起源于间皮细胞,总体预后极差,胸膜受累最常见,腹膜受累少见。
- WHO将间皮瘤分为上皮样、双相型和肉瘤样组织学亚型,肉瘤样或双相型预后最差。
- 间皮瘤呈独特的环状生长模式,医学影像评估颇具挑战;传统影像以增强CT为主,功能与代谢影像被视为补充手段。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malignant mesothelioma is an aggressive tumor originating from the mesothelial cells and presenting in general with a very poor prognosis. The pleural localization represents the prevailing disease site, while peritoneal involvement is commonly rare. The WHO classifies mesotheliomas into epithelioid, biphasic, and sarcomatoid histotypes, having diverse outcome with the sarcomatoid or biphasic forms showing the poorest prognosis. Given the peculiar rind-like pattern of growth, mesothelioma assessment is rather challenging for medical imagers. Conventional imaging is principally based on contrast-enhanced CT, while the role of functional and metabolic imaging is regarded as complementary. By focusing essentially on the staging and restaging role of [18F]FDG PET/CT in malignant mesotheliomas, the present review will summarize the available data present in literature and provide some hints on alternative imaging and future perspectives. Given the prevailing incidence of pleural disease, the majority of the information will be addressed on malignant pleural mesothelioma, although a summary of principal characteristics and imaging findings in patients with peritoneal mesothelioma will be also provided.
引用
- Lopci E, Castello A, Mansi L, et al. FDG PET/CT for Staging and Restaging Malignant Mesothelioma. Semin Nucl Med. 2022. PMID: 35965111. doi:10.1053/j.semnuclmed.2022.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。